EXPLORING THE INTERPLAY BETWEEN INFLAMMATORY SKIN DISORDERS AND CARDIOVASCULAR HEALTH
Main Article Content
Keywords
Inflammatory skin disorders, Psoriasis, cardiovascular diseases, atherosclerosis,, coronary artery disease, systemic anti-inflammatory therapies, integrated management
Abstract
Background: the therapeutic use of anti-inflammatory drugs on the body for the treatment of cardiovascular and cutaneous ailments. Thorough patient evaluations and data analysis yielded important insights that shed light on potential choices for integrated management approaches.
Objectives: This research aimed to evaluate the complex relationship between inflammatory skin illnesses, notably psoriasis, and cardiovascular comorbidities, with an emphasis on atherosclerosis and coronary artery disease (CAD).
Study design: A retrospective study.
Duration and place of study: inflammatory skin disorders, primarily psoriasis, the study was conducted at PIMS Hospital Islamabad from 05-January 2022-05-January 2023.
Methods: a retrospective investigation on 100 patients suffering from inflammatory skin illnesses, mostly psoriasis. Patient information, including as demographics, the extent of skin disease, cardiovascular risk factors, imaging findings, and specifics of the course of therapy, were carefully recorded and examined. The purpose of the research was to determine how common cardiovascular comorbidities were in these individuals and how well systemic anti-inflammatory medications worked to treat both skin and cardiovascular symptoms. Statistical techniques were used in the data analysis to assess relationships between treatment results, cardiovascular risk factors, and the severity of skin diseases.
Results: The correlation that has been noted between cardiovascular illnesses and inflammatory skin conditions emphasizes the need of a multidisciplinary approach to patient therapy. Therapy that targets common inflammatory pathways may be able to reduce cardiovascular risks in addition to treating the cutaneous symptoms. Working together, cardiologists, rheumatologists, and dermatologists can optimise treatment plans and enhance overall patient results.
Conclusion: The study emphasises how closely inflammatory skin conditions, especially psoriasis, are related to cardiovascular risk. Promising in the management of both cutaneous and cardiovascular symptoms, systemic anti-inflammatory treatments underscore the need of integrated care methods. To clarify underlying processes and confirm best practices in therapy, further study is necessary.
Objectives: This research aimed to evaluate the complex relationship between inflammatory skin illnesses, notably psoriasis, and cardiovascular comorbidities, with an emphasis on atherosclerosis and coronary artery disease (CAD).
Study design: A retrospective study.
Duration and place of study: inflammatory skin disorders, primarily psoriasis, the study was conducted at PIMS Hospital Islamabad from 05-January 2022-05-January 2023.
Methods: a retrospective investigation on 100 patients suffering from inflammatory skin illnesses, mostly psoriasis. Patient information, including as demographics, the extent of skin disease, cardiovascular risk factors, imaging findings, and specifics of the course of therapy, were carefully recorded and examined. The purpose of the research was to determine how common cardiovascular comorbidities were in these individuals and how well systemic anti-inflammatory medications worked to treat both skin and cardiovascular symptoms. Statistical techniques were used in the data analysis to assess relationships between treatment results, cardiovascular risk factors, and the severity of skin diseases.
Results: The correlation that has been noted between cardiovascular illnesses and inflammatory skin conditions emphasizes the need of a multidisciplinary approach to patient therapy. Therapy that targets common inflammatory pathways may be able to reduce cardiovascular risks in addition to treating the cutaneous symptoms. Working together, cardiologists, rheumatologists, and dermatologists can optimise treatment plans and enhance overall patient results.
Conclusion: The study emphasises how closely inflammatory skin conditions, especially psoriasis, are related to cardiovascular risk. Promising in the management of both cutaneous and cardiovascular symptoms, systemic anti-inflammatory treatments underscore the need of integrated care methods. To clarify underlying processes and confirm best practices in therapy, further study is necessary.
References
1. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735-1741.
2. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2(2):e000062.
3. Miller IM, Ellervik C, Yazdanyar S, Jemec GB. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69(6):1014-1024.
4. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866-873.
5. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev. 2007;65(12 Pt 2):S253-S259.
6. Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130(7):1785-1796.
7. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000-1006.
8. Gisondi P, Targher G, Cagalli A, Girolomoni G. Hyperuricemia in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014;70(1):127-130.
9. Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130(7):1785-1796.
10. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000-1006.
11. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2(2):e000062.
12. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735-1741.
13. Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27-40.
14. Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, Kaufmann R, Vogl TJ, Boehncke WH. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007;156(2):271-6.
15. Davidovici BB, Sattar N, Jörg PC, Puig L, Emery P, Barker JN, Van De Kerkhof P, Ståhle M, Nestle FO, Girolomoni G, Krueger JG. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. Journal of Investigative Dermatology. 2010 Jul 1;130(7):1785-96.
16. Hickey NA, Shalamanova L, Whitehead KA, Dempsey-Hibbert N, van der Gast C, Taylor RL. Exploring the putative interactions between chronic kidney disease and chronic periodontitis. Critical reviews in microbiology. 2020 Jan 2;46(1):61-77.
2. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2(2):e000062.
3. Miller IM, Ellervik C, Yazdanyar S, Jemec GB. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69(6):1014-1024.
4. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866-873.
5. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev. 2007;65(12 Pt 2):S253-S259.
6. Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130(7):1785-1796.
7. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000-1006.
8. Gisondi P, Targher G, Cagalli A, Girolomoni G. Hyperuricemia in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014;70(1):127-130.
9. Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130(7):1785-1796.
10. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000-1006.
11. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2(2):e000062.
12. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735-1741.
13. Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27-40.
14. Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, Kaufmann R, Vogl TJ, Boehncke WH. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007;156(2):271-6.
15. Davidovici BB, Sattar N, Jörg PC, Puig L, Emery P, Barker JN, Van De Kerkhof P, Ståhle M, Nestle FO, Girolomoni G, Krueger JG. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. Journal of Investigative Dermatology. 2010 Jul 1;130(7):1785-96.
16. Hickey NA, Shalamanova L, Whitehead KA, Dempsey-Hibbert N, van der Gast C, Taylor RL. Exploring the putative interactions between chronic kidney disease and chronic periodontitis. Critical reviews in microbiology. 2020 Jan 2;46(1):61-77.
Article Sidebar
Published
Feb 15, 2024
Article Details
How to Cite
Sadia Anwar, faryl afridi, Farrakh Ghayas, & Maria Saleem. (2024). EXPLORING THE INTERPLAY BETWEEN INFLAMMATORY SKIN DISORDERS AND CARDIOVASCULAR HEALTH. Journal of Population Therapeutics and Clinical Pharmacology, 31(2), 764-768. https://doi.org/10.53555/jptcp.v31i2.4468
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biographies
Sadia Anwar
Sr.Medical Officer/Post Graduate Resident MCPS
faryl afridi
Post Graduate Resident FCPS
Farrakh Ghayas
Post Graduate Resident , Md
Maria Saleem
FCPS Assistant Professor
How to Cite
Sadia Anwar, faryl afridi, Farrakh Ghayas, & Maria Saleem. (2024). EXPLORING THE INTERPLAY BETWEEN INFLAMMATORY SKIN DISORDERS AND CARDIOVASCULAR HEALTH. Journal of Population Therapeutics and Clinical Pharmacology, 31(2), 764-768. https://doi.org/10.53555/jptcp.v31i2.4468